Spontaneous and pharmacologically induced remissions in patients with premature ovarian failure.
To determine the fertility potential of patients with apparent ovarian failure, a retrospective analysis of 86 ovarian failure patients in the Norfolk oocyte donation program was performed. None of the 23 patients with primary ovarian failure ovulated. Seven of 63 (11.1%) with secondary ovarian failure did ovulate, and three of 63 (4.8%) conceived and delivered normal, healthy infants. Of patients whose etiology for ovarian failure was partial ovarian resection or chemotherapy, the ovulation rate and pregnancy rate were 30.8 and 15.4%, respectively, compared with 5.0 and 1.7%, respectively, for the other patients with secondary ovarian failure. Serum estradiol and FSH obtained during hormone replacement were not predictive of the resumption of normal reproductive functions. Therefore, it is recommended that patients with secondary ovarian failure, especially in the better-prognosis group, be treated with a trial of estradiol replacement and have close monitoring for ovulation before oocyte donation.
D000328:Adult; D000568:Amenorrhea / Q000209:etiology; D004958:Estradiol / Q000097:blood / Q000627:therapeutic use*; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D008593:Menopause / Q000187:drug effects*; D008594:Menopause, Premature / Q000187:drug effects*; D010049:Ovarian Diseases / Q000188:drug therapy; D010062:Ovulation Induction; D011247:Pregnancy; D011374:Progesterone / Q000627:therapeutic use*; D012074:Remission Induction; D012075:Remission, Spontaneous; D012189:Retrospective Studies
D011374:Progesterone; D004958:Estradiol; D005640:Follicle Stimulating Hormone